Class / Patent application number | Description | Number of patent applications / Date published |
424425000 | Diffusion barrier is matrix | 40 |
20080260800 | EXTRACELLULAR MATRIX CANCER VACCINE ADJUVANT - Compositions suitable for use as adjuvants in the preparation of vaccines, particularly those vaccines useful in the treatment of cancer, are provided. Methods for inhibiting tumor growth in an animal are also disclosed. Methods for immunizing an animal against cancer, such as prostate cancer, are also described. The adjuvants described are comprised of an extracellular matrix material, such as small intestinal submucosal (SIS) tissue. The preparations may take the form of sheets, gels, liquids (injectable), trocar, or other solid or semi-solid preparation. The invention provides for enhanced tumor inhibition of 2-fold or greater, compared to vaccine preparations without the extracellular matrix material, or from 4- to 5-fold, compared to preparations without the adjuvant promoting extracellular materials. | 10-23-2008 |
20080274161 | HYDROGELS AND HYDROGEL PARTICLES - The invention provides fabricated hydrogels, hydrogel particles, hydrogel containing compositions, and methods of making the same. The invention also provides methods of implanting, injecting, or administering the hydrogels, hydrogel particles, or the hydrogel containing compositions to treat a subject in need. Methods of crosslinking pre-solidified or pre-gelled hydrogel particles and making crosslinked hydrogels, crosslinked hydrogel particles, and crosslinked hydrogel containing compositions also are disclosed herein. | 11-06-2008 |
20080286333 | Medical devices having coating with improved adhesion - According to an aspect of the present invention, a medical device is provided which comprises a metallic substrate and polymeric region disposed over and in contact with the metallic substrate. The polymeric region comprises (a) a block copolymer that comprises (i) a hard polymer block that comprises a high Tg monomer and (ii) a soft polymer block that comprises a low Tg monomer, (b) an adhesion promoting copolymer that comprises (i) a first monomer that covalently or non-covalently bonds with the metallic substrate and (ii) a second monomer that is compatible with the low Tg monomer and/or the high Tg monomer and (c) a therapeutic agent. The polymeric region may further comprise an optional polymer that is used to tailor the release rate of the therapeutic agent. | 11-20-2008 |
20090022777 | Methods for progenitor cell recruitment and isolation - The invention relates to the use of one or more growth factors in a drug delivery system, optionally with an external mesh housing, to recruit and optionally harvest progenitor cells. These cells include those that normally reside in the bone marrow. | 01-22-2009 |
20090087474 | Therapeutic use of growth factors,nsg29 and nsg31 - The present invention relates to the field of therapeutic use of proteins, genes and cells, in particular to the therapy based on secreted therapeutic proteins, NsG29 and NsG31. NsG29 and Ns31 are members of a newly identified family of growth factors with a specific cystein pattern and characterised by expression in the nervous system. The secreted growth factors have potential for the treatment of disorders of the nervous system. The invention also relates to bioactive NsG29 and NsG31 polypeptide fragments and the corresponding encoding DNA sequences. | 04-02-2009 |
20090123520 | Keloid Therapy - Therapeutic compositions, devices and protocols for the treatment of keloids and other abnormal scars with improved appearance and a much lower recurrence rate. A therapeutic drug delivery device comprises an injectable mixture of a fibroblast inhibitor such as corticosteroid and a slow release carrier such as milled gel sponge dispersed in a fluid medium such as biological saline. The composition can be injected perilesionally in the dermis following excision of the keolid or other scar tissue, to circumscribe the wound. The infiltration of the mixture around the wound can provide a slow release of the fibroblast inhibitor for an extended period of time until normal wound closure can dominate and keloid or abnormal scar recurrence is inhibited. | 05-14-2009 |
20090136561 | Non-peptidyl agents with pHSP20-like activity, and uses thereof - The present invention provides compositions and methods for modulating smooth muscle cells. The present invention also provides methods of identifying small molecule candidate therapeutic agents for modulating smooth muscle. | 05-28-2009 |
20090246252 | Insertable medical devices having microparticulate-associated elastic substrates and methods for drug delivery - The present invention provides insertable medical devices having elastic surfaces associated with bioactive agent-containing microparticulates and a coating material. Upon expansion of the elastic surfaces the microparticulates can be released to a subject. | 10-01-2009 |
20090269389 | ARPE-19 as a Platform Cell Line for Encapsulated Cell-Based Delivery - ARPE-19 cells were evaluated as a platform cell line for encapsulated and unencapsulated cell-based delivery technology. ARPE-19 cells were found to be hardy (the cell line is viable under stringent conditions, such as in central nervous system or intra-ocular environment); can be genetically modified to secrete the protein of choice; have a long life span; are of human origin; have good in vivo device viability; deliver efficacious quantity of growth factor; trigger no or low level host immune reaction, and are non-tumorigenic. | 10-29-2009 |
20090297583 | POLY(ESTER AMIDES) FOR THE CONTROL OF AGENT-RELEASE FROM POLYMERIC COMPOSITIONS - The present invention generally encompasses a medical article, such as a medical device or coating comprising an agent or combination of agents, wherein the agent is distributed throughout a polymeric matrix. The polymeric matrix comprises an agent and a poly(ester amide) having a design that was preselected to provide a predetermined release rate of the combination of agents from the medical article. | 12-03-2009 |
20100015205 | BIOCOMPATIBLE AMINO ACID ANHYDRIDE POLYMERS - Biocompatible amino acid anhydride polymers for use in tissue engineering, and methods for their preparation and use. | 01-21-2010 |
20100047316 | REPAIR OF CARTILAGE TISSUE USING A MATRIX GEL CONTAINING CHONDROCYTES - The present invention relates in one aspect to the use of a matrix gel comprising chondrocytes or progenitor cells thereof in a density below that of natural cartilage as a cartilage repair implant wherein said cells exhibit increases production of extracellular matrix material. | 02-25-2010 |
20100047317 | USING BUCKY PAPER AS A THERAPEUTIC AID IN MEDICAL APPLICATIONS - Methods, systems, and uses of bucky paper are provided in the present invention. These embodiments include covering medical implants with single or multiple layers of bucky paper, treating bucky paper with various therapeutics to be released through the bucky paper to a target site, shaping bucky paper into non-conventional configurations for improved therapeutic deliver, and using bucky paper alone or in conjunction with other materials to treat a target site. | 02-25-2010 |
20100055149 | RE-ROLLABLE WRAPPING IMPLANT - A re-rollable membrane for wrapping around and protecting a cylindrical tissue having an injury site. The membrane includes a sheet of a porous matrix formed of cross-linked biopolymeric fibers. In one implementation, the sheet can be spirally rolled so that at least one portion overlaps another portion of the sheet and, upon absorption of a fluid, the overlapping portions adhere to each other closely so as to exclude penetration of cells. In another implementation, the sheet can be helically rolled to form a helix having a pitch of 2 mm to 40 mm and an inner diameter of 1 mm to 50 mm. Also disclosed are methods for making and using such re-rollable membranes. | 03-04-2010 |
20100055150 | METHOD AND COMPOSITION FOR TREATMENT OF SKELETAL DYSPLASIAS - The present invention relates to a method for the treatment of skeletal dysplasia by administering to a patient a composition comprising a therapeutically effective amount of at least one C-type natriuretic peptide (CNP). | 03-04-2010 |
20100112033 | STENTS COATED WITH NO- AND S-NITROSOTHIOL-ELUTING HYDROPHLIC POLYMERIC BLENDS - This invention relates to stents coated with hydrophilic polymers containing S-nitrosothiols, which are able to provide local delivery of both nitric oxide and S-nitrosothiols by diffusion. This device is intended for coronary angioplasty applications with the purpose of inhibiting acute and chronic restenosis and refers to processes of stent coating with hydrophilic polymers containing incorporated S-nitrosothiols. This invention refers to an intracoronary implant device used in medical procedures, and introduces new S nitrosothiol-eluting stents coated with hydrophilic polymer multilayers. The hydrophilic polymers used for coating are polyvinyl alcohol, polyvinylpirrolidone and polyvinyl alcohol/polyvinylpirrolidone, polyvinyl alcohol/polyethylene glycol, polyvinylpirrolidone/polyethylene glycol and polyvinyl alcohol/polyvinylpirrolidone/polyethylene glycol blends. The S-nitrosothiols incorporated to the polymer coatings are mainly primary S-nitrosothiols, characterized by the fact of the nitric oxide (NO) molecule being covalently bound to a sulfur (S) atom which, in turn, is linked to a primary carbon in the molecule's structure, thus constituting the S—NO chemical group. The coating processes include immersion of the stents in polymer solutions containing S-nitrosothiols and nebulization processes of the polymer solutions containing S-nitrosothiols onto the stent surface. | 05-06-2010 |
20100129421 | COMPOSITION FOR PROMOTING BONE REGENERATION AND RESTORATION - A bone grafting material composite is provided. The bone grafting material composite includes a demineralized bone matrix (DBM) and a carboxymethyl cellulose (CMC)/glycerol gel carrier. Due to the CMC/glycerol gel carrier, the implantation ability thereof is better than that of the DBM. Therefore, the bone grafting material composite can be easily used, so that a curative effect can be greatly improved. In addition, since the CMC/glycerol gel is used as a carrier, the composite with a mobility maintained is washed out by water after surgery, so that the composite can be fixed on a damaged portion of a bone. | 05-27-2010 |
20100136085 | COMPOSITIONS AND METHODS FOR ARTHRODETIC PROCEDURES - The present invention provides compositions and methods for facilitating fusion of bones in a joint. The present invention provides compositions and methods for promoting fusion of bones in arthrodetic procedures. In one embodiment, a method of performing an arthrodetic procedure comprises providing a composition comprising PDGF disposed in a biocompatible matrix and applying the composition to a site of desired bone fusion in a joint. | 06-03-2010 |
20100226959 | MATRIX THAT PROLONGS GROWTH FACTOR RELEASE - An implantable matrix is provided, the matrix having a porous interior configured to release a growth factor and to allow influx of at least progenitor, bone and/or cartilage cells therein; and a biodegradable membrane disposed on the porous interior, the biodegradable membrane being less porous than the porous interior and configured to retain the growth factor and release the growth factor from the porous interior as the biodegradable membrane degrades at or near the target tissue site. In some embodiments, a method for making the implantable collagen matrix is provided, the method comprising: providing a porous collagen layer configured to release a growth factor and to allow influx of at least progenitor, bone and/or cartilage cells therein, and disposing a collagen membrane on the porous collagen layer, the collagen membrane being less porous than the porous collagen layer and configured to retain the growth factor. | 09-09-2010 |
20100303888 | COMPOSITION FOR ENHANCING BONE FORMATION - Disclosed herein is a matrix for inducing or enhancing osteoclast differentiation. The matrix comprises a material having an osteoclastogenic agent associated therewith, the agent being releasable from the material in an amount which is sufficient to induce or enhance osteoclast differentiation. | 12-02-2010 |
20110008408 | SOLID DOSAGE FORM FOR TREATING HEADACHES - A retrievable, sustained release, solid dosage form is provided for implanting into cranial bony canals and for prolonged release of an anesthetic, whereby treating neurovascular conditions, such as migraine. The dosage comprises an anesthetic contained in a polymeric carrier, and a retrieval member, the anesthetic being gradually released from the carrier. | 01-13-2011 |
20110027339 | POROUS IMPLANTS AND STENTS AS CONTROLLED RELEASE DRUG DELIVERY CARRIERS - The common premise of synthetic implants in the restoration of diseased tissues and organs is to use inert and solid materials. Here, a porous titanium implant enables the delivery of microencapsulated bioactive cues. Control-released TGFβ1 promoted the proliferation and migration of human mesenchymal stem cells into porous implants in vitro. Upon 4-wk implantation in the rabbit humerus, control-released TGFβ1 from porous implants significantly increased BIC by 96% and bone ingrowth by 50% over placebos. Control-released 100 ng TGFβ1 induced equivalent BIC and bone ingrowth to adsorbed 1 μg TGFβ1, suggesting that controlled release is effective at 10-fold less drug dose than adsorption. Histomorphometry, SEM and μT showed that control-released TGFβ1 enhanced bone ingrowth in the implant's pores and surface. These findings suggest that solid prostheses can be transformed into porous implants to serve as drug delivery carriers, from which control-released bioactive cues augment host tissue integration. | 02-03-2011 |
20110070284 | BIOLOGIC MATRICES COMPRISING ANTI-INFECTIVE METHODS AND COMPOSITIONS RELATED THERETO - Described herein are methods and compositions related to biologic matrices comprising at least one anti-infective. In certain embodiments, the invention relates to a biologic matrix comprising a slowed release anti-infective agent. In a particular embodiment, the invention relates to an acellular dermal matrix comprising a slowed release antiinfective agent, wherein the anti-infective agent is triclosan. In further embodiments, the the biologic matrix is suitable for use in surgical procedures, such as, for example, for the replacement of damaged or inadequate integumental tissue or for the repair, reinforcement or supplemental support of soft tissue defects. | 03-24-2011 |
20110076318 | RETINOID-CONTAINING SUSTAINED RELEASE INTRAOCULAR IMPLANTS AND RELATED MATTERS - Biocompatible intraocular implants include a retinoid component and a biodegradable polymer that is effective to facilitate release of the retinoid component into an eye for an extended period of time. The therapeutic agents of the implants may be associated with a biodegradable polymer matrix, such as a matrix that is substantially free of a polyvinyl alcohol. The implants may be placed in an eye to treat or reduce the occurrence of one or more ocular conditions, such as retinal damage, including glaucoma and proliferative vitreoretinopathy. | 03-31-2011 |
20110159072 | CONTROLLED RELEASE MATRIX - A biocompatible polymeric controlled release matrix for delivery of one or more bioactive agents from an implantable medical device is described. In one embodiment, the polymeric controlled release matrix is a complaint film that includes one or more compliant biocompatible polymers and one or more bioactive agents. In another embodiment, the polymeric controlled release matrix is an elastomeric collar that includes one or more elastomeric biocompatible polymers and one or more bioactive agents. | 06-30-2011 |
20110165219 | OPTIMIZATION OF ALGINATE ENCAPSULATION OF ISLETS FOR TRANSPLANTATION - Apparatus is provided, including a plurality of islets, and a hydrogel configured to macroencapsulate the plurality of islets. The hydrogel is implantable in a subcapsular space ( | 07-07-2011 |
20110244016 | MEDICAL IMPLANT HAVING A COATING COMPOSED OF OR CONTAINING AT LEAST ONE ACTIVE SUBSTANCE - One embodiment of the invention relates to a medical implant whose surface is completely or partially covered by a coating composed of at least one active substance or containing at least one active substance. | 10-06-2011 |
20120141573 | Cell Lines That Secrete Anti-Angiogenic Antibody-Scaffolds and Soluble Receptors and Uses Thereof - The invention provides nucleic acid and polypeptide sequences encoding antibody based scaffolds such as full antibodies, antibody Fab fragments, single chain antibodies, soluble VEGF receptor-Fc fusion proteins, and/or anti-angiogenic PDGF receptors. Also encompassed are cell lines encoding such anti-angiogenic antibody scaffolds, VEGF receptors, and/or PDGF receptors. The invention also provides encapsulated cell therapy devices that are capable of delivering such anti-angiogenic antibody scaffolds, VEGF receptors, and/or PDGF receptors as well as methods of using these devices to deliver the anti-angiogenic antibody scaffolds, VEGF receptors, and/or PDGF receptors to medically treat disorders in patients, including ophthalmic, vascular, inflammatory, and cell proliferation diseases. | 06-07-2012 |
20120288551 | Implantable Polymeric Device for Sustained Release of Sufentanil - Extended release of sufentanil is provided by implanting a device containing sufentanil into a mammal or human being. The device may include a solid biocompatible polymer matrix, and sufentanil may be encapsulated within the polymer matrix. The polymer matrix comprises a plurality of pores configured to allow contact between the sufentanil and a physiological fluid of a mammal into which the device is implanted to thereby release sufentanil in vivo from the device into the mammal. The devices may be used to treat opioid addiction or pain. | 11-15-2012 |
20130004559 | FLAT SELF-CURLING PERMEABLE SHEET MEMBRANE - A flat self-curling permeable sheet membrane containing a matrix formed of crosslinked biopolymeric fibers. The matrix self-curls into a predetermined shape upon absorption of an aqueous fluid and is permeable to molecules having molecular weights not greater than 1×10 | 01-03-2013 |
20140134226 | COMPOSITIONS AND METHODS FOR INHIBITING BONE GROWTH - Compositions and methods are provided for a matrix that inhibits bone growth in a patient in need thereof. In one embodiment, a method of inhibiting bone growth is provided, the method comprising: implanting a matrix at a target tissue site, the matrix comprising a biodegradable polymer and dextran loaded in the matrix in an amount of from about 5% to about 95% by weight based on a total weight of the matrix. | 05-15-2014 |
20140161860 | Implantable Polymeric Device for Sustained Release of Buprenorphine - The present invention provides compositions, methods, and kits for treatment of opiate addiction and pain. The invention provides a biocompatible nonerodible polymeric device which releases buprenorphine continuously with generally linear release kinetics for extended periods of time. Buprenorphine is released through pores that open to the surface of the polymeric matrix in which it is encapsulated. The device may be administered subcutaneously to an individual in need of continuous treatment with buprenorphine. | 06-12-2014 |
20140242144 | DRUG ELUTING SCAFFOLD FOR KIDNEY-RELATED DISEASE - Methods of treating renal cancers and other kidney-related inflammatory disorders with a bioabsorbable polymer scaffold (such as a stent) are described. The treatments are provided as alternative to complete or partial surgical removal of a diseased kidney. | 08-28-2014 |
20150024025 | ALIGNED NANOFIBROUS STRUCTURES FOR AXONAL REGENERATION AFTER SPINAL CORD INJURY OR SURGERY - Embodiments of the present disclosure provide for aligned nanofibrous polymer matrix structure, structures incorporating aligned nanofibrous polymer matrix structures, methods of using aligned nanofibrous polymer matrix structures, methods of making aligned nanofibrous polymer matrix structures, and the like. | 01-22-2015 |
20150140061 | COATED STENT COMPRISING AN HMG-CoA REDUCTASE INHIBITOR - Stents with coatings comprising a combination of a restenosis inhibitor comprising an HMG-CoA reductase inhibitor and a carrier. Also provided are methods of coating stents with a combination of an HMG-CoA reductase inhibitor and a carrier. A preferred example of a restenosis inhibitor is cerivastatin. The stent coatings have been shown to release restenosis inhibitors in their active forms. | 05-21-2015 |
20150366956 | Scaffolds For Cell Transplantation - A device that includes a scaffold composition and a bioactive composition with the bioactive composition being incorporated into or coated onto the scaffold composition such that the scaffold composition and/or a bioactive composition controls egress of a resident cell or progeny thereof. The devices mediate active recruitment, modification, and release of host cells from the material. | 12-24-2015 |
20160022570 | MEDICAL IMPLANT - An improved medical implant device directed to, inter alia, (i) avoiding unwanted initial drug “burst” problems, (ii) providing a more level amount of drug delivery, (iii) reducing blood clotting, (iv) reducing the amount of drug material that remains in the implant device, and/or (v) novel materials for an implant device. | 01-28-2016 |
20160121024 | BONE DEFECT FILLING MATERIAL, AND PRODUCTION METHOD THEREFOR - Rebuilding a defected bone by activating the innate self-regeneration ability of bone requires a considerably long period of time. The purpose of the present invention is to provide a bone defect filling material that initiates a bone rebuilding activity as quickly as possible after implantation and thereafter remains in the defect to continue promoting bone formation activity until sufficient bone formation has been achieved for the rebuilding of the defect. The present invention provides a cotton-like bone defect filling material comprising biodegradable fibers produced by electrospinning. The biodegradable fibers contain 40-60 wt % of calcium phosphate particles and 10 wt % or more of silicon-releasing calcium carbonate particles, with the remainder containing 30 wt % or more of poly(L-lactic acid) polymer, and the amount of the poly(L-lactic acid) polymer that is non-crystalline is 75-98%. | 05-05-2016 |
20160250393 | NANOFIBER MATS, METHOD OF MANUFACTURING THE NANOFIBER MATS, AND APPLICATIONS TO CELL CULTURE AND NANOFIBROUS MEMBRANE FOR GUIDED BONE REGENERATION | 09-01-2016 |
20180021479 | BONE DEFECT FILLING MATERIAL, AND PRODUCTION METHOD THEREFOR | 01-25-2018 |